MHC II immunogenicity shapes the neoepitope landscape in human tumors

Jeong Yeon Kim(Korea Advanced Institute of Science and Technology), Jung Kyoon Choi(Korea Advanced Institute of Science and Technology), Kyeonghui Kim(Korea Advanced Institute of Science and Technology), Se‐Hoon Lee(Samsung Medical Center), Incheol Shin(Hanyang University), Jinhyeon An(Korea Advanced Institute of Science and Technology), Hongui Cha(Cancer Research UK), Hyoeun Bang(Korea Advanced Institute of Science and Technology), Seung-Jae Noh, Dae-Yeon Cho(TiGenix (Spain)), Hyungjoo Kim(Hanyang University), Changhwan Sung(Ulsan College), Inkyung Shin(Hanyang University), Jin Ok Yang(Korea Advanced Institute of Science and Technology), Suhwan Chang(Ulsan College)
Nature Genetics
January 9, 2023
10.1038/s41588-022-01273-y
Cited by 37

Related Papers

Randomized Phase III KEYNOTE-181 Study of Pembrolizumab Versus Chemotherapy in Advanced Esophageal Cancer
|Journal of Clinical Oncology|2020|1.2k
Perioperative Pembrolizumab for Early-Stage Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2023|1k
Lung adenocarcinoma promotion by air pollutants
|Nature|2023|751
Neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab compared with neoadjuvant chemotherapy alone in patients with early-stage non-small-cell lung cancer (KEYNOTE-671): a randomised, double-blind, placebo-controlled, phase 3 trial
|The Lancet|2024|233
HERTHENA-Lung01, a Phase II Trial of Patritumab Deruxtecan (HER3-DXd) in Epidermal Growth Factor Receptor–Mutated Non–Small-Cell Lung Cancer After Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy and Platinum-Based Chemotherapy
|Journal of Clinical Oncology|2023|224